PHIO (Phio Pharmaceuticals Corp.) stock: $0.80, $9.3M market cap, $10.6M cash, -$1.3M EV, $20.6M fully diluted market cap. Lead program: PH-762 (Squamous Cell Carcinoma of the Skin; Malignant Melanoma of Skin; Merkel Cell Carcinoma of Skin), Phase 1. Data from Fully Diluted's biotech stocks database.
What they do
We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note INTASYL self-delivering siRNA compound. Evaluated via intratumoral administration in a U.S. multi-center Phase 1b dose-escalating trial in cSCC.
PH-894
Preclinical · ActiveModality: siRNA
Target BRD4
Indications
Cancer(Preclinical)
Status note INTASYL compound targeting BRD4. Preclinical; the Company is weighing whether/when to fund additional pipeline programs including PH-894.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
PH-762
Lead indication
Squamous Cell Carcinoma of the Skin; Malignant Melanoma of Skin; Merkel Cell Carcinoma of Skin
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.